Clinical trials: HIV Antibodies
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
Healthy, HIV
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
The proposed study is a first-in-man phase I study that aims to evaluate the safety, tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and its antiretroviral activity in HIV-infected…
- Trial name
- NCT02018510
- Testing
- 1 mg/kg, single dose IV administration of 3BNC117, 3 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, single dose IV administration of 3BNC117
- Where
- 4 sites in United States, Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV-1-infection
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
- Trial name
- NCT06987318
- Testing
- VRC07-523LS, PGT121.414.LS
- Where
- 13 sites in United States, Brazil and 1 more
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV
There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma.
- Trial name
- AbVax (NCT07054931)
- Testing
- ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv4
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University of Oxford
HIV
VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption
Background: A combination of daily drugs (called cART) can keep human immunodeficiency virus (HIV) very low for a long time. But cART can lose effectiveness and cause permanent side effects.
- Trial name
- NCT02471326
- Testing
- VRC-HIVMAB060-00-AB (VRC01)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infections, HIV Infections
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
HIV-infected people and pregnant women are at risk of developing severe pneumococcal disease. The purpose of this study is to compare the safety and immune response to two pneumococcal vaccines in HIV-infected pregnant women.
- Trial name
- NCT01443117
- Testing
- PPV-23 Vaccine, PCV-13 Vaccine
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults
Background: HIV (human immunodeficiency virus) is the virus that causes AIDS (acquired immunodeficiency syndrome). Researchers want to find new ways to treat or prevent HIV infection.
- Trial name
- NCT06585891
- Testing
- VRC-HIVMAB0121-00-AB
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic HIV Infection
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
- Trial name
- NCT06006546
- Testing
- 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
3BNC117-LS First-in-Human Phase 1 Study
The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are…
- Trial name
- NCT03254277
- Testing
- 3BNC117-LS
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
COVID-19 Prevalence in HIV-infected Patients
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them…
- Trial name
- SeCoVIHA (NCT04515225)
- Testing
- Blood Sample
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Human Immunodeficiency Virus Infection, Hepatitis C
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
The purpose of this study is to compare the results for HIV and/or Hepatitis C Virus antibody testing when using routine plasma versus SMARTplasma from the same blood sample.
- Trial name
- NCT01447680
- Where
- 7 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
HIV Infection
Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation
The availability of antiretroviral therapy (cART) for HIV-1 infection has led to a reduction in morbidity in patients with chronic HIV infection.
- Trial name
- ITATI (NCT04720742)
- Testing
- Analytical Treatment Interruption + bNAbs infusion
- Where
- 4 sites in Italy, Netherlands and 1 more
- Sponsor
- IrsiCaixa
HIV Infection, Hepatitis C
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV).
- Trial name
- NCT01423643
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- Johns Hopkins University
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy, HIV
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
- Trial name
- NCT02511990
- Testing
- 3 mg/kg, single dose IV administration of 10-1074, 10 mg/kg, single dose IV administration of 10-1074, 30 mg/kg, single dose IV administration of 10-1074
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV-1 Infection
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of…
- Trial name
- NCT02446847
- Testing
- 3BNC117, ART Interruption
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rockefeller University
HIV Infections
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test
To determine the efficacy of an improved rapid diagnostic test using venous whole blood and fingerstick whole blood. The clinical performance of Reveal G4 Rapid HIV-1 Antibody Test will be determined by comparing the results with…
- Trial name
- NCT02190578
- Testing
- Reveal G4
- Where
- 4 sites in United States
- Volunteers
- 1,649 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
Acute HIV Infection
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: Administration of…
- Trial name
- NCT05719441
- Testing
- VRC07-523LS, PGT121.414.LS, ART
- Where
- 12 sites in United States, Brazil and 1 more
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kaposi Sarcoma, HIV Infection
Development of Serologic Assays for Human Herpes Virus-8
Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins.
- Trial name
- NCT00395278
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV
Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza
As recommended by the Dutch Health Council, certain risk groups and health care workers in The Netherlands were vaccinated to prevent morbidity due to pandemic influenza A/H1N1.
- Trial name
- RICH-3 (NCT01066169)
- Testing
- Foceteria® (Novartis)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center